Enhancing the Efficacy of Immunotherapeutic Drugs for Prostate Cancer – Dr Douglas McNeel, MD PhD, University of Wisconsin

Jun 14, 2019 | biology, health and medicine

Prostate cancer is a leading cause of male cancer deaths worldwide, with one man in every seven likely to contract the disease during his lifetime. As late-stage prostate cancer remains a fatal disease resistant to conventional treatment, the need for effective new therapies is dire. Dr Douglas McNeel, a Professor of Medicine in the Haemato-Oncology Division of the University of Wisconsin’s Carbone Cancer Centre, has been working to meet this need.

Original article reference:

https://doi.org/10.33548/SCIENTIA346

More SciPods you may like

Understanding Lassa virus – Dr Matthew Boisen, Zalgen Labs

For many years, Dr Matthew Boisen, Director of Diagnostics Development at Zalgen Labs, has focussed on trying to understand Lassa fever. Part of the Viral Hemorrhagic Fever Consortium, his group’s objectives are threefold: first, to develop fast and accurate...

Did you enjoy this SciPod? Do you want your own?